← Back to Search

Cagrilintide 2.4 mg for Type 2 Diabetes

Phase 2
Waitlist Available
Research Sponsored by Novo Nordisk A/S
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from baseline (week 0) to week 37
Awards & highlights

Study Summary

This study is evaluating whether a new medicine called cagrilintide works better with semaglutide than cagrilintide alone or semaglutide alone.

Eligible Conditions
  • Type 2 Diabetes

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from baseline (week 0) to week 37
This trial's timeline: 3 weeks for screening, Varies for treatment, and from baseline (week 0) to week 37 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Glycated Haemoglobin (HbA1c): Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Semaglutide 2.4 mg + Placebo (Cagrilintide)
Secondary outcome measures
CGM: Change in Mean Glucose: Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Cagrilintide 2.4 mg + Placebo (Semaglutide)
Change in Body Weight (Kilogram): Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Semaglutide 2.4 mg + Placebo (Cagrilintide)
Change in Fasting Plasma Glucose (FPG): Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Semaglutide 2.4 mg + Placebo (Cagrilintide)
+6 more

Side effects data

From 2022 Phase 2 trial • 92 Patients • NCT04982575
29%
Nausea
16%
Constipation
16%
Diarrhoea
16%
COVID-19
10%
Fatigue
10%
Vomiting
10%
Gastrooesophageal reflux disease
6%
Upper respiratory tract infection
6%
Back pain
6%
Hiccups
6%
Eructation
6%
Gastroenteritis
6%
Sinusitis
3%
Arthralgia
3%
Injection site reaction
3%
Dizziness
100%
80%
60%
40%
20%
0%
Study treatment Arm
Semaglutide 2.4 mg + Placebo (Cagrilintide)
Cagrilintide 2.4 mg + Semaglutide 2.4 mg
Cagrilintide 2.4 mg + Placebo (Semaglutide)

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: Cagrilintide 2.4 mg and semaglutide 2.4 mgExperimental Treatment2 Interventions
Participants will receive cagrilintide and semaglutide once a week as injections for 32 weeks.
Group II: Cagrilintide 2.4 mg and placebo (semaglutide)Active Control2 Interventions
Participants will receive cagrilintide and placebo (semaglutide) once a week as injections for 32 weeks
Group III: Semaglutide 2.4 mg and Placebo (cagrilintide)Active Control2 Interventions
Participants will receive semaglutide and placebo (cagrilintide) once a week as injections for 32 weeks
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cagrilintide 2.4 mg
2021
Completed Phase 2
~100
Semaglutide 2.4 mg
2021
Completed Phase 3
~1640

Find a Location

Who is running the clinical trial?

Novo Nordisk A/SLead Sponsor
1,514 Previous Clinical Trials
2,414,973 Total Patients Enrolled
Clinical Transparency (dept. 1452)Study DirectorNovo Nordisk A/S
56 Previous Clinical Trials
45,028 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

How old are they?
18 - 65
What portion of applicants met pre-screening criteria?
Did not meet criteria
Recent research and studies
clinicaltrials.govStudy
Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes
2021. "Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04982575.
~25 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top